The facility is located outside of the free trade zone (FTZ) in Tangzhen near Catalent’s Waigaoqiao FTZ site and China’s Zhangjiang Pharma Valley area. The company expects the site to employ up to 100 people.
The company announced its plans to invest $2.5m in the new clinical supply late last year.
Read: Catalent’s China expansion to meet growing clinical trial industry
Catalent will provide various clinical supply services including FastChain demand-led supply, secondary packaging, clinical storage, and local distribution form the facility. It also will conduct clinical returns and destruction services.
"The facility's location, outside of Shanghai’s Free Trade Zone, helps Catalent’s customers by providing easier importation into China for trials in the country. In providing a more efficient, timely way of getting supplies to where customers want them, it minimizes transit time and risk of excursions of limited-shelf life products," a Catalent spokesperson previously told us.
Catalent earlier this year invested $5m in a drug development center of excellence to expand its hot melt extrusion capabilities for formulation and drug delivery method optimization.
